TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT
RESEARCH BIBLIOGRAPHY
1976 – 2010


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)

RS 3012  Getz K.  FIPNet: pharma’s new, sexy, but not yet ready for print-time model.  *Applied Clinical Trials* 2009 Nov;Suppl:10-12,14,16


RS 3009  Getz KA.  Sizing up the clinical research market.  *Applied Clinical Trials* 2010 Mar;19(3):32-4

RS 3008  Getz KA.  With clinical data, less is more.  *Applied Clinical Trials* 2010 Jan;19(1)


RS 3004  Kaitin KI.  Deconstructing the drug development process: the new factor of innovation.  *Clinical Pharmacology and Therapeutics* 2010 Mar;87(3):356-61

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website  [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2934  Getz KA  Vogel JR.  Successful outsourcing: tracking global CRO usage.  *Applied Clinical Trials Online* 2009 Aug 17  


RS 2932  Getz KA.  Is an investigative site shake-out imminent?  *Applied Clinical Trials* 2009 Nov;18(11)  

RS 2931  Bridges JFP Cohen JP  Grist PG  Muhlbacher AC.  International experience with comparative effectiveness research: case studies from England/Wales and Germany.  In:  *Pharmaceutical markets and insurance worldwide*. Edited by Dor, A.  (Volume 22 of Advances in health economics and health services research)  
Emerald Books: Bingley UK, 2010:29-50*


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website  http://csdd.tufts.edu


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS2913-A  Getz KA.  Are academia and NIH bastions of integrity?  *Applied Clinical Trials* 2009 Jul;18(7)  


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)

RS2910-A  Getz KA. A compelling need to usher in alliances. *Applied Clinical Trials* 2009

RS 2910  Kaitin KI, editor. Therapeutic peptides in clinical study in 2000—07 nearly
doubled 1990s rate. *Tufts Center for the Study of Drug Development Impact
Report* 2009 May/Jun;11(3)**

RS 2909  Kaitin KI, editor. In-licensing/out-licensing strategies and practices. *Tufts Center

RS 2908  Kaitin KI, editor. Change and opportunity in the Phase I landscape. *Tufts Center

RS 2907  Reichert JM Nelson AL. Development trends for therapeutic antibody
fragments. *Nature Biotechnology* 2009 Apr;27(4):331-7

RS 2906  DiMasi JA  Faden L. Factors associated with multiple FDA review cycles and

RS 2905  Kaitin KI, editor. 75% of U.S. health plans reimburse off-label uses of
prescription drugs. *Tufts Center for the Study of Drug Development Impact
Report* 2009 Mar/Apr;11(2)**

RS 2904  Reichert JM  Rochon SL  Zhang BF. Finding value in the U.S. Food and Drug
Administration’s Fast Track Program. *Drug News Perspectives* 2009
Jan/Feb:22(1):53-8

RS 2903-B  Kaitin KI. The landscape for pharmaceutical innovation: drivers of cost-effective
clinical research. *Pharmaceutical Outsourcing* 2009 Jan-Feb:7-9

RS 2903-A  Cohen J Wilson A. New challenges to Medicare beneficiary access to mAbs.
*mAbs* 2009 Jan/Feb;1(1):1-11

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 2831  Milne C-P  Bruss JB.  The economics of pediatric formulation development for off-patent drugs.  *Clinical Therapeutics* 2008 Nov;30(11):2133-45


RS 2827  Kaitin KI, editor.  Fast track designations more than doubled during the last five years.  *Tufts Center for the Study of Drug Development Impact Report* 2008 Sep/Oct;10(5)**


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)
| RS 2825 | Getz KA. Public confidence and trust today. *ACRP Monitor* 2008 Sep;22(5):17-21 |

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
| RS 2815 | Getz K. Beyond outsourcing (interview by Jenefer Trevena). *Scrip Supplement Contract Research Update* 2008 Apr;4:5-6 |
| RS 2807 | Kaitin KI, editor. Number of mAbs entering clinical study nearly tripled in last decade. *Tufts Center for the Study of Drug Development Impact Report* 2008 Mar/Apr;10(2)** |

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2729  Getz KA. In search of informed consent improvement. Applied Clinical Trials 2007 Nov;16(11):42,44-5 http://www.actmagazine.com/appliedclinicaltrials/Clinical+Trial+Insights/In-Search-of-Informed-Consent-Improvement/ArticleStandard/Article/detail/468090


RS 2727  Cohen J. CEA is not a price control (letter) Health Affairs 2007;26(5):1505 http://content.healthaffairs.org/cgi/reprint/26/5/1505

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 2723  Getz KA. Global clinical trials activity in the details. *Applied Clinical Trials* 2007 Sep;16(9):42-4


RS 2721  Kaitin KI, editor. Despite more cancer drugs in R&D, overall U.S. approval rate is 8%. *Tufts Center for the Study of Drug Development Impact Report* 2007 Sep/Oct;9(5)**

http://www.springerlink.com/content/f03333rv1823w611/fulltext.pdf


RS 2717  Getz KA. CRA: jack of all trades. *Applied Clinical Trials* 2007 July;16(7):36,8
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=439804

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2714  Getz KA. CRO shifts in the outsourcing market. *Applied Clinical Trials* 2007 May;16(5):35-6,8  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=424918


RS 2711  Getz KA. Industry trials poised to win back academia. *Applied Clinical Trials* 2007 Apr;16(4):40-2,4  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416536

RS 2710  Getz KA, Sergeant E, Kremidas J. Mission possible: rebranding clinical research. *Applied Clinical Trials* 2007 Apr;16(4):35-6,8  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=416537


RS 2708  Getz K, Wenger J. High times for the CRO heavyweights. *Scrip supplements* 2007 Mar;5-6  


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)*


RS 2704  Getz KA. Drowning in the sea of regulatory compliance. *Applied Clinical Trials* 2007 Feb;16(2):32, 34  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=401621


RS 2626  Getz KA. Hitching a ride with the speed demons of drug development. *Applied Clinical Trials* 2006 Dec;15(12):22,24  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=392454

http://www.thescientist.com/article/display/36886/

RS 2624  Cohen J  Cairns C  Paquette C  Faden L. Comparing patient access to pharmaceuticals in the UK and US. *Applied Health Economics and Health Policy* 2006;5(3):177-87


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=382875


RS 2619  Getz KA. Spotting the 'new' managed site networks. *Applied Clinical Trials* 2006 Sep;15(9):34,36  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=370345


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=334568

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
Kaitin KI, editor. CRO contribution to drug development is substantial and growing globally. *Tufts Center for the Study of Drug Development Impact Report* 2006 Jan/Feb;8(1)**

http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=282477

Getz KA. The imperative to support site adoption of EDC. *Applied Clinical Trials* 2006 Jan;15(1):38, 40  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=283027


http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=261633

Getz KA. Have we pushed our PIs too far? *Applied Clinical Trials* 2005 Sep;14(9):34-6  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=176904&&pageID=1

http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172272

Milne C-P Kaitin KI. Down the critical path: who should lead? *Applied Clinical Trials* 2005 Aug;14(8):56  
http://www.actmagazine.com/appliedclinicaltrials/article/articleDetail.jsp?id=172279


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)

RS 2512  DiMasi JA  Hansen RW  Grabowski HG. Reply: setting the record straight on setting the record straight: response to the Light and Warburton rejoinder. *Journal of Health Economics* 2005 Sep;24(5):1049-53


RS 2510  Kaitin KI, editor. Longer clinical times are extending time to market for new drugs in U.S. *Tufts Center for the Study of Drug Development Impact Report* 2005 Nov/Dec;7(6)**


Also available at http://www.nature.com/nbt/journal/v23/n9/pdf/nbt0905-1073.pdf


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 2501  Kaitin KI, editor. Decline in drug approvals is driving industry, FDA to enhance efficiency. Tufts Center for the Study of Drug Development Impact Report 2005 Jan/Feb;7(1)**


RS 2423  Milne C-P. Harbingers, or harvesters of change? European Pharmaceutical Review Supplement (Outsourcing) 2004 Winter:12-17


RS 2419  Cohen J. The emergence of a de facto fourth hurdle in the US. Regulatory Affairs Journal -- Pharma 2004 Dec;15(12):867-70

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2312 Kaitin KI, editor. Switching drugs from prescription to OTC status on rise in U.S. and EU. *Tufts Center for the Study of Drug Development Impact Report* 2003 Sep/Oct;5(5)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)*


RS 2304  Milne C-P.  Exploring the frontiers of law and science: the FDAMA’s pediatric studies initiative.  *Food and Drug Law Journal*  2002;57(3):491-517  


RS 2301  Kaitin KI, editor.  Increased pressure on drug industry is leading to greater focus on Japan.  *Tufts Center for the Study of Drug Development Impact Report* 2003 Jan/Feb;5(1)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website  http://csdd.tufts.edu**


RS 2218  Kaitin KI, editor.  Approval times for new drugs fell by more than a year during PDUFA. *Tufts Center for the Study of Drug Development Impact Report* 2002 Nov/Dec;4(6)**

RS 2217  Franco RJ  Kaitin KI.  Beyond the blockbuster: big pharma must rethink product development, striving for the speed and flexibility of mid-size players. *Pharmaceutical Executive* 2002 Nov;22(11):74-80  
http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=36729


RS 2213  Kaitin KI, editor.  Approval times for priority-reviewed new drugs declined under PDUFA. *Tufts Center for the Study of Drug Development Impact Report* 2002 Jul/Aug;4(4)**

http://www.nature.com/nbt/journal/v20/n7/pdf/nbt0702-659.pdf

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)
Cohen J  Chee J. Pharmacy benefit managers’ role in facilitating Medicare beneficiary access to pharmaceutical care. *Disease Management & Health Outcomes* 2002;10(4):221-7


Reichert JM Therapeutic monoclonal antibodies: trends in development and approval in the US. *Current Opinion in Molecular Therapeutics* 2002;4(2):110-8

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2123  Kaitin KI. El papel de la investigación básica. [editorial]. (Original title: The quest for cures -- the role of the research-based drug industry) La Vanguardia (Barcelona) 2001 18 Mar*

RS 2122  Kaitin KI, participant. The importance of innovation in pharmaceutical research. Pfizer Journal 2001;4(5)


RS 2119  DiMasi JA. Winners and losers in new drug innovation. Medical Marketing & Media 2001 Sep;36(9):99-110


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


*http://www.diahome.org/DIAHome/resources/content.aspx?type=eopdf&file=%2fproductfiles%2f8357%2fdiaj_11681.pdf*


*http://www.diahome.org/DIAHome/resources/content.aspx?type=eopdf&file=%2fproductfiles%2f8357%2fdiaj_11725.pdf*

RS 2110  Kaitin KI, editor.  Pharmaceutical firms making quicker decisions on compounds in R&D.  *Tufts Center for the Study of Drug Development Impact Report* 2001 May/Jun;3(3)**


RS 2106  Kaitin KI, editor.  Tufts Center survey describes disease management practice in the U.S.  *Tufts Center for the Study of Drug Development Impact Report* 2001 Mar/Apr;3(2)**

* This publication is not available from the Center.  Please contact a library or the publisher.

** This publication is for sale at our website *http://csdd.tufts.edu*


RS 2102  Kaitin KI, editor.  FDA’s fast track program results in 62% approval rate after first 3 years. *Tufts Center for the Study of Drug Development Impact Report* 2001 Jan/Feb;3(1)**


http://www.diahome.org/content/abstract/2000/dij1556.pdf

RS 2023  Cross-functional team focus on marketing is key to project success. *Tufts Center for the Study of Drug Development Impact Report* 2000 Dec;2(9)  

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 2018  Kaitin KI.  Don’t turn back the clock on drug regulatory reform.  *Tufts Center for the Study of Drug Development Impact Editorial* 2000 Sep;2(7)


http://www.acnp.org/g4/GN401000182/Default.htm

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website  http://csdd.tufts.edu**


RS 2009  Influence of pharmacoeconomics in drug R&D decisions is growing. Tufts Center for the Study of Drug Development Impact Report 2000 May;2(4)  

RS 2008  Drug firms embrace pediatric study program during first 2 years of FDAMA. Tufts Center for the Study of Drug Development Impact Report 2000 Apr;2(3)  


RS 2004  European approval of new biotech drugs outpaces US approval. Tufts Center for the Study of Drug Development Impact Report 2000 Mar;2(2)  


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9901  Kaitin KI. Global drug development and international harmonization: the emergence of China as a world pharmaceutical player. Drug Information Journal 1998;32(Suppl):1187s-92s


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu

RS 9810  Lasagna L. Presentation of the Louis Lasagna Chair of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine. Journal of Clinical Pharmacology 1998;38:570-1, 575-6


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


RS 9715  Kaitin KI. FDA reform: setting the stage for efforts to reform the agency. Drug Information Journal 1997;31(1):27-33

RS 9714  Lasagna L DiMasi JA. Let’s speed up the approval of new indications for old drugs. Medical Marketing & Media 1996 Dec;31(12):88-9


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
<table>
<thead>
<tr>
<th>RS 9625</th>
<th>DiMasi JA. <em>Written testimony</em>. House Subcommittee on Human Resources and Intergovernmental Affairs, Committee on Government Reform and Oversight, U.S. House of Representatives. September 12, 1996</th>
</tr>
</thead>
<tbody>
<tr>
<td>RS 9623</td>
<td>Kaitin KI. <em>Statement</em>. Hearing before the Subcommittee on Health and Environment of the Committee on Commerce, House of Representatives. The Need for FDA Reform, February 27, 1996. 104th Congress 2d Session:81-7, 100-1</td>
</tr>
</tbody>
</table>

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9506 Shulman SR Seibring M Manocchia M. *Letter to Hon. Judd Gregg, U.S. Senate.* Hearing before the Subcommittee on Aging of the Committee on Labor and Human Resources, United States Senate, July 13, 1995 104th Congress 1st Session:47-8

RS 9505 Lasagna L. *Statement; drugs and biologics: FDA review process.* Hearings before the Subcommittee on Oversight and Investigations of the Committee on Commerce, U.S. House of Representatives, June 19, 1995 104th Congress 1st Session:130-8


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

DiMasi J Grabowski HG Vernon J. R&D costs, innovative output and firm size in the pharmaceutical industry. *International Journal of the Economics of Business* 1995 Jul;2(2):201-19


Brown JS DiMasi JA Gosse ME Manocchia M Kaitin KI Shulman SR. Incentives for the development of drugs for AIDS and other life-threatening illnesses: points to consider. For the Public/Private Issues and Development Subcommittees of the National Task Force on AIDS Drug Development meeting, April 25, 1995


Bloom BR. The United States needs a national vaccine authority. *Science* 1994 Sep 2;265(5177):1378-80


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9496 Lasagna L. *Statement of Louis Lasagna, M.D., Dean, Tufts Sackler School of Graduate Biomedical Sciences at the National Institutes of Health CRADA forum, July 21, 1994*. Washington DC: New England Biomedical Research Coalition, 1994


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9485  Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News* 1993 Nov;(8)


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 9274  Shulman SR  Raiford DS.  Promotional elements in educational programs: FDA attempts to wipe the slate clean.  *P&T* 1992;17:661-73*


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>RS 9266</td>
<td>Scoville B. Shifting the burden: restructuring the drug review process. <em>Journal of Clinical Pharmacology and Therapeutics</em> 1991 Mar;49(3):229-33</td>
</tr>
</tbody>
</table>

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**
RS 9162 Inman WHW. Drug Safety Research Unit, University of Southampton. PEM News 1991 Aug;(7)


RS 9158 DiMasi JA Lasagna L. Development of supplemental indications for already-approved drugs by the United States pharmaceutical industry. Journal of Clinical Research and Pharmacoepidemiology 1991;5:19-33


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
RS 9054  Shulman SR. La legislazione sulla responsabilità di produzione. Informazioni Stampa Interesse Sanitario (Rome) 1990 Apr 9;#15:27-8

RS 9053  Lasagna L. Le attività del Centro per lo Studio dello Sviluppo dei Farmaci. Informazioni Stampa Interesse Sanitario (Rome) 1990 Apr 9;#15:26

RS 9052  Inman WHW. Drug Safety Research Unit, University of Southhampton, PEM News 1988 Sep(5)


RS 9050  Lasagna L. On achieving consensus regarding flexible therapeutic end points. Drug Information Journal 1990;24:231-4


RS 9048  Shulman SR Raiford DS. FDA regulations provide broader access to unapproved drugs. Journal of Clinical Pharmacology 1990;30:585-7


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


Kaitin KI. Reply to “understanding comparisons of drug introductions between the United States and the United Kingdom”. *Clinical Pharmacology & Therapeutics* 1989 Aug;46(2):146-8


Grabowski HG. Medicaid patients' access to new drugs. *Health Affairs* 1989;7:102-14


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


Inman WHW. Drug Safety Research Unit, University of Southampton. *PEM News* 1988 Sep;(5)


Shulman SR. Drug refusal policy must include legal definition of competence. *Hospital Formulary* 1988 Jan;23:79

DiMasi JA. The notion of "acceptable risk": comment. *Journal of Clinical Epidemiology* 1988;41(9):939-41


Wittes RE. Antineoplastic agents and FDA regulations: square pegs for round holes? *Cancer Treatment Reports* 1987;71:795-806

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu**
RS 8718  Lasagna L.  The biological revolution: commercialization of the molecule.  

RS 8717  Lasagna L.  Predicting human drug safety from animal studies: current issues.  

RS 8716  Lasagna L.  The desire to regulate: the wish to discover.  Drugs Under 
Experimental and Clinical Research 1987;13(11):659-64

RS 8715  Barash CI  Lasagna L.  The Bendectin saga: "voluntary" discontinuation.  Journal 

RS 8714  Spivey RN  Lasagna L  Trimble AG.  New indications for already-approved 
drugs: time trends for the new drug application review phase.  Clinical 
Pharmacology and Therapeutics 1987 Apr;41(4):368-70

RS 8713  Richard BW  Lasagna L.  Drug regulation in the United States and the United 
Jun;106(6):886-91

RS 8712  Scheuplein RJ.  Risk assessment and food safety: a scientist's and regulator's 

PS 8711  Lasagna L, editor.  Center for the Study of Drug Development Conference on 
Postmarketing Surveillance of Multisource Drugs, July 9-10, 1986.  Boston: Tufts 
CSDD, 1986

RS 8710  Inman WHW.  Drug Safety Research Unit, University of Southampton,  PEM 
News 1987 Mar;(4)

RS 8709  Venulet J.  Informativity of adverse drug reactions data in medical publications.  
Drug Information Journal 1985;19:357-65

RS 8708  Lasagna L.  On reducing waste in foreign clinical trials and postregulation 

RS 8707  Grabowski HG.  Health care cost containment and pharmaceutical innovation.  In: 
Pharmaceuticals for the elderly: new research and new concerns.  Washington 
DC: Pharmaceutical Manufacturers Association, Office of Policy Analysis, 
1986:25-8

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu

RS 8705  Kaitin KI. Impact of generic drugs on the pharmaceutical marketplace. *Private Practice* 1986 Sep;18:18-20  (Originally appeared as "Generic firms shun research, share rewards.")


RS 8600  Berry CL. Unprovable verities. *Human Toxicology* 1985;5(3):159-60

RS 8699  Weintraub M  Northington F. Drugs that wouldn't die. *Journal of the American Medical Association* 1986 May 2;255(17):2327-8


RS 8696  Inman WHW. Drug Surveillance Research Unit, University of Southampton. *PEM News* 1985 Dec;(3)


RS 8691  Walker SR  Schultz E  Schuppan D  Gelzer J. A comparative retrospective analysis of data for short- and long-term animal toxicity studies on 40 pharmaceutical compounds. *Archives of Toxicology* 1984;7:485-7

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 8591 Mattison N. Sources of change affecting the U.S. pharmaceutical industry in the 1980s. Pharmaceutical Medicine 1985;1:13-6*


RS 8588 Waife SO Lasagna L. From DNA to NDA--the impact of recombinant DNA technology on new drug development. Regulatory Toxicology and Pharmacology 1985;5(2):212-24


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 8477  Inman WHW. Drug Surveillance Research Unit, University of Southampton, PEM News 1984 Aug;(2)


RS 8474-B  Weintraub M. P&T committees and drug regulation in Norway: lessons to be learned. Hospital Formulary 1984;19:347

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


Hutt PB. The importance of patent term restoration to pharmaceutical innovation: will extending patent life increase drug innovation? A search for answers. *Health Affairs* 1982;1(2):5-24


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

RS 8367  Superior Court of New Jersey, Appellate Division. Carol Ann Feldman, an infant, by her parent and guardian ad litem Harold Feldman, Plaintiffs vs. Lederle Laboratories, a corporation, and American Cyanamid Co., a corporation, Defendants - Respondents. Nov 1983

RS 8366  Inman WHW. Drug Surveillance Research Unit, University of Southampton. PEM News 1983 Aug;(1)

RS 8365  Covington TR. Toward a rational approach to the issue of prescribing authority for pharmacists. Drug Intelligence and Clinical Pharmacy 1983 Sep;17(9):660-6


RS 8363  Young JH. Public policy and drug innovation. The American Institute of the History of Pharmacy 1982;24:1-56

RS 8362  Paton WD. Animal experimentation and medical research: a study in evolution. Conquest 1979 Feb;169:1-14

RS 8361  Hutt PB. Investigations and reports respecting FDA regulation of new drugs, Part I) and Part II. Clinical Pharmacology and Therapeutics 1983;33(4):537-48; 33(5):674-87


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu
RS 8359-C  Diggle GE  Griffin JP. Licensing times in granting marketing authorizations for medicines—a comparison between the U.K. and U.S.A.  Pharmacy International 1982;3(7):230-6


RS 8262  Wardell WM. Is pharmaceutical innovation declining?  Pharmaceutical Technology 1982 Sep


RS 8260  Wardell WM  Mattison N. The assessment of medical technologies using risk-benefit, cost-benefit, and cost-effectiveness analysis. In: WMA Follow-up Committee on Development and Allocation of Medical Care Resources. Tokyo: Japan Medical Association, 1982;84-98*

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 8252 Shubin S. The MAC program and advisors to the government. *Hospital Formulary* 1981 Aug;16(8):869-79


RS 8250 Wardell WM. *A statement on pharmaceutical patent life and innovation.* Submitted to the Subcommittee on Investigations and Oversight of the Committee on Science and Technology, U.S. House of Representatives. Feb 4, 1982

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


* This publication is not available from the Center. Please contact a library or the publisher.  
**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)

RS 8059  Hansen RW. *Effects of incremental costs on pharmaceutical innovation.* (Working Paper Series No. GPB-81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

RS 8058  Hansen RW. *The cost of regulation in the pharmaceutical industry: economic implications of three recent studies.* (Working Paper Series No. PS 81-2) Rochester NY: Graduate School of Management, University of Rochester, Dec 1980

RS 8057  Wardell WM. Therapeutic drugs as an example of the regulation of health care: efficient and inefficient ways of utilizing resources. In: *Proceeding of the World Medical Association Follow-Up Committee Meeting on Development and Allocation of Medical Care Resources.* Tokyo: Japan Medical Association, 1980:139-50*

RS 8056  Wardell WM. Drug therapy (a response to questions on specific aspects of drug regulation). *Private Practice* 1980 Oct:24-31*


RS 8051  Lasagna L. Pharmacology's labs have moved faster than the regulators. *Medical Tribune* 1980 May 7;21:17

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 8046  Hansen RW. Pharmaceutical development costs by therapeutic categories. (Working Paper Series No. GPB-80-6) Rochester NY: Graduate School of Management, University of Rochester, Mar 1980*


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


RS 8039  Letters to the editor. in re: the drug lag. Regulation 1980 Mar/Apr;4(2):59-60


PS 8032  Merrill RA. Problems involving federal conflict of interest restrictions on members of FDA advisory committees and agency officials. Rochester NY: Center for the Study of Drug Development, Apr 1980

RS 8031  Lasagna L. Who will adopt the orphan drugs? Regulation 1979 Nov/Dec;(6):27-32

* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website http://csdd.tufts.edu


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

RS 7939  Lasagna L.  Toxicological barriers to providing better drugs.  *Archives of Toxicology* 1979;43(1):27-33

RS 7938  Lasagna L.  Prescription drugs: the investment with the biggest dividends.  *Private Practice* 1979 May;11(5):42-3


RS 7930  Lasagna L.  The uncertain future of drug development.  *Drug Intelligence and Clinical Pharmacy* 1979 Apr;13(4):192-4

* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


RS 7926-A  Lasagna L.  The diseases and drug needs of the Third World.  *Journal of Chronic Diseases* 1979;32(6):413-4


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**

RS 7828 Lasagna L. Generic substitution: trick or treat? *Journal of the American Medical Association* 1978 May 5;239(18):1888


RS 7825 Wardell WM. History and application of drug safety and efficacy requirements in the United States. *Agents and Action* 1978; 8(4):420-1*


RS 7823 Wardell WM. A close inspection of the 'calm look': rhetorical amblyopia and selective amnesia at the FDA. *Journal of the American Medical Association* 1978;239(19):2004-11


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


PS 7816 Landau RL. *What you should know about estrogens, or the perils of Pauline*. Rochester NY: Center for the Study of Drug Development, Jun 1978


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)


* This publication is not available from the Center.  Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)**


* This publication is not available from the Center. Please contact a library or the publisher.

**This publication is for sale at our website [http://csdd.tufts.edu](http://csdd.tufts.edu)